Condition
Extensive-Stage Small Cell Lung Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 16 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
16 shownAutologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNCT07509034 · 2026-10-12
RECRUITINGA Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)NCT07652736 · 2026-06-05
RECRUITINGA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25
RECRUITINGMaintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCNCT06497530 · 2024-12-01
RECRUITINGA Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung CancerNCT07796100 · 2026-12-31
NOT_YET_RECRUITINGBispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerNCT07328490 · 2026-04-25
WITHDRAWNSacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNCT07388875 · 2026-02-24
NOT_YET_RECRUITINGA Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung CancerNCT06614621 · 2025-02-01
NOT_YET_RECRUITINGEfficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung CancerNCT06554535 · 2024-10-01
NOT_YET_RECRUITINGMDT-Based Nursing for Small Cell Lung Cancer During Chemo-ImmunotherapyNCT07489339 · 2024-07-01
COMPLETEDSurufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerNCT05509699 · 2022-09-27
COMPLETEDA Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung CancerNCT04404543 · 2020-06-01
UNKNOWNEfficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide ChemotherapyNCT04056949 · 2019-08-05
UNKNOWNStudy of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)NCT01555710 · 2012-06-08
TERMINATEDA Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung CancerNCT01076504 · 2009-12-01
COMPLETEDSunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLCNCT00616109 · 2007-09-01
COMPLETEDCommon interventions
CarboplatinDRUG4EtoposideDRUG3Adebrelimab +Etoposide+Platinum-based drugsDRUG1AmrubicinDRUG1AnlotinibDRUG1Anti-PD-1/L1DRUG1AtezolizumabBIOLOGICAL1Autologous B7-H3 CAR TDRUG1BMS-986489 (Atigotatug+Nivolumab)BIOLOGICAL1Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with LurbinectedinCOMBINATION_PRODUCT1Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenanceCOMBINATION_PRODUCT1CyclophosphamideDRUG1FludarabineDRUG1IBI308DRUG1LurbinectedinDRUG1Maintenance treatment period:DRUG1Multidisciplinary Team-Based Nursing InterventionOTHER1Paclitaxel/Albumin-Bound PaclitaxelDRUG1Palifosfamide-trisDRUG1PegfilgrastimDRUG1Routine Nursing CareOTHER1Sacituzumab GovitecanDRUG1Sacituzumab TirumotecanDRUG1SerplulimabDRUG1Serplulimab,Platinum-based Chemotherapy,AspirinDRUG1
Leading sponsors
National Cancer Institute (NCI)
2
Alaunos Therapeutics
1
BeOne Medicines
1
Bristol-Myers Squibb
1
China Medical University, China
1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
1
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
1
Fujian Cancer Hospital
1
Guangzhou Institute of Respiratory Disease
1
Hutchison Medipharma Limited
1
Junling Li
1
SCRI Development Innovations, LLC
1
Shanxi Province Cancer Hospital
1
University of Michigan Rogel Cancer Center
1
Zai Lab (Shanghai) Co., Ltd.
1
Trial status mix
COMPLETED4
NOT_YET_RECRUITING4
RECRUITING4
UNKNOWN2
TERMINATED1
WITHDRAWN1
Phase mix
PHASE29
PHASE13
PHASE33
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.